

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Osmotica Corp.	11/13/2004
RECEIVING PARTY DATA	
Name:	Osmotica Holdings Corp. A.V.V.
Street Address:	Samuel Lewis Ave. & 54th St.
Internal Address:	AFRA Building
City:	Panama
State/Country:	PANAMA
PROPERTY NUMBERS Total: 4	
Property Type	Number
Patent Number:	6004582
Patent Number:	RE39069
Patent Number:	6613357
Patent Number:	7147870
CORRESPONDENCE DATA	
Fax Number:	(972)747-7375
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	9727477373
Email:	innovarllc@sbcglobal.net
Correspondent Name:	Rick Matos
Address Line 1:	P.O. Box 250647
Address Line 2:	Innovar LLC
Address Line 4:	Plano, TEXAS 75025-0647
ATTORNEY DOCKET NUMBER:	PHUS-0
NAME OF SUBMITTER:	RICK MATOS

CH \$160.00 6004582

501516260

PATENT
REEL: 026202 FRAME: 0244

Total Attachments: 5

source=asgn_OSCorp_to_OSHold#page1.tif

source=asgn_OSCorp_to_OSHold#page2.tif

source=asgn_OSCorp_to_OSHold#page3.tif

source=asgn_OSCorp_to_OSHold#page4.tif

source=asgn_OSCorp_to_OSHold#page5.tif

ASSIGNMENT OF PATENT RIGHTS

WHEREAS, OSMOTICA CORP. ("Assignor"), a corporation organized and existing under the laws of the British Virgin Islands, is the owner of the inventions or improvements and applications in the United States of America and in any and all countries corresponding to the serial numbers and filing dates as set forth in Exhibit A attached hereto ("the Patent"); and

WHEREAS, OSMOTICA HOLDINGS CORP. A.V.V. ("Assignee"), a corporation organized and existing under the laws of Aruba, having its principal office and place of business in Aruba, is desirous of obtaining the entire right, title and interest in, to and under the Patent;

NOW, THEREFORE, for One Dollar (US\$1.00) and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto said Assignee, its successors, legal representatives, and assigns, the entire right, title and interest in, to and under said inventions, and applications, and all provisional, divisional, renewal, substitutional, and continuing applications thereof, and all Letters Patent of the United States of America which may be granted thereon and all reissues, reexaminations and extensions thereof, and all applications for Letters Patent which may be filed for said inventions in any country or countries foreign to the United States of America, and all Letters Patent, Utility Model, Petty Patent, Design Patent, and Design Registration which may be granted for said inventions in any country or countries foreign to the United States of America, and all extensions, renewals, reexaminations and reissues thereof, and Assignor hereby authorizes and requests the Commissioner of Patents of the United States of America, and any official of any country or countries foreign to the United States of America, whose duty it is to issue patents on applications as aforesaid, to issue all Letters Patent for said inventions to said Assignee, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR HEREBY covenants that it has full right to convey the entire interest herein assigned, and that it has not executed, and will not execute, any agreement in conflict herewith.

AND ASSIGNOR HEREBY further covenants and agrees that it will communicate to said Assignee, its successors, legal representatives and assigns, any facts known to Assignor respecting said inventions, and testify in any legal proceedings, sign all lawful papers, execute all divisional, renewal, substitutional, continuing, and reissue applications, make all rightful declarations and/or oaths and generally do everything possible to aid said Assignee, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for said inventions in all countries.

IN TESTIMONY WHEREOF,

Assignor hereunto sets its hand
OSMOTICA CORP.

Date: November 13, 2004



Abdiel Mansfield, acting for and on
behalf of InterCorp Services, Inc.,
Sole Director of Osmotica Corp.

EXHIBIT A

No.	Title (Country)	Patent No.	Issue Date MM/DD/YY	Serial No.	Filing Date MM/DD/YY
1	Multi-layered osmotic device (U.S.)	US 6,004,582	12/21/99	US 09/086,871	05/29/98
2	Multi-layered osmotic device (Europe)	EP 0914098	10/01/03	EP 98925026. 0	01/22/99
3	Multi-layered osmotic device (Canada)	Pending Allowed	—	CA 2,261,787	01/28/99
4	Multi-layered osmotic device (China)	Pending Allowed	—	CN 98800728. 2	01/29/99
5	Multi-layered osmotic device (Japan)	Pending Allowed	—	JP 500972/19 99	01/29/99
6	Multi-layered osmotic device (Israel)	Pending Allowed	—	IL 128,043	01/14/99
7	Multi-layered osmotic device (Hong Kong)	HK 1019859	01/30/04	HK 99105177. 6	11/10/99
8	Multi-layered osmotic device (U.S. reissue)	Pending	—	US 10/004,772	12/03/01
9	Multi-layered osmotic device (France)	EP 0914098	10/01/03	EP 98925026. 0	01/22/99
10	Multi-layered osmotic device (Germany)	EP 0914098	10/01/03	DE 69818607. 9	11/27/03
11	Multi-layered osmotic device (Italy)	EP 0914098	10/01/03	EP 98925026. 0	03/29/98
12	Multi-layered osmotic device (Spain)	EP 0914098	10/01/03	EP 98925026. 0	01/22/99
13	Multi-layered osmotic device (United Kingdom)	EP 0914098	10/01/03	EP 98925026. 0	01/22/99
14	Osmotic Device Containing Pseudoephedrine and an H1 Antagonist. (U.S.)	U.S. 6,613,357	09/02/03	U.S. 09/725,655	11/29/00
15	Osmotic Device Containing Pseudoephedrine and an H1 Antagonist. (Europe)	Pending	—	EP 01900942. 2	07/09/02
16	Osmotic Device Containing Pseudoephedrine and an H1 Antagonist. (Canada)	Pending	—	CA 2,396,145	01/08/01
17	Osmotic Device Containing Pseudoephedrine and an H1 Antagonist. (U.S.)	Pending	—	U.S. 10/643,011	08/18/03


ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, OSMOTICA CORP., a British Virgin Islands corporation, ("Osmotica"), does hereby sell, transfer, assign, set over, deliver and convey unto OSMOTICA HOLDINGS CORP. A.V.V., an Aruba corporation, all of Osmotica's rights and obligations under that certain Cooperative Venture Agreement between APPLIED ANALYTICAL INDUSTRIES HOLDING LIMITED and Osmotica dated as of June 23, 2000, as amended (the "AAI Agreement").

Osmotica makes this assignment without recourse and does not make, has not made and shall not be deemed to have made any warranty or representation, express, implied or statutory, as to the effectiveness, validity, legality or enforceability of the AAI Agreement.

IN WITNESS WHEREOF, Osmotica has caused this Assignment to be executed as of the 13th day of November, 2004.

OSMOTICA CORP.

By: 
Abdiel Mansfield, acting for
and on behalf of Intercorp
Services, Inc., Sole Director of
Osmotica Corp.

RESOLUTION OF THE SOLE DIRECTOR OF
OSMOTICA CORP.

The undersigned, INTERCORP SERVICES INC., being the Sole Director of OSMOTICA CORP., a corporation organized and existing under the laws of the British Virgin Islands (the "Company"), hereby consents to the adoption of the following resolutions:

RESOLVED, that the Company be and is hereby authorized to transfer to OSMOTICA HOLDINGS CORP. A.V.V., a corporation organized and existing under the laws of Aruba, as a dividend the inventions or improvements, as the case may be, and applications corresponding to the serial numbers and filing dates as set forth in Exhibit A attached hereto (the "Patent"); and

FURTHER RESOLVED, that the Company be and is hereby authorized to distribute as a dividend the assignment of its rights and obligations under that certain Cooperative Venture Agreement between Applied Analytical Industries Holding Limited and the Company dated as of June 23, 2000, as amended (the "Agreement"); and

FURTHER RESOLVED, that Intercorp Services Inc., the Sole Director of the Company, be and is hereby authorized to execute and deliver on behalf of the Company, any and all agreements, documents or instruments relating thereto, as may be necessary or advisable to effect the aforementioned transfer of the Patent and the assignment of the Agreement as a dividend, in such form and containing such terms and conditions as the Sole Director shall approve, and that execution thereof by the Sole Director shall constitute conclusive evidence of such approval.

Dated this 13th day of November, 2004.



Abdiel Mansfield, acting for and
on behalf of INTERCORP
SERVICES INC., Sole Director

EXHIBIT A

No.	Title (Country)	Patent No.	Issue Date MM/DD/YY	Serial No.	Filing Date MM/DD/ YY
1	Multi-layered osmotic device (U.S.)	US 6,004,582	12/21/99	US 09/086,871	05/29/98
2	Multi-layered osmotic device (Europe)	EP 0914098	10/01/03	EP 98925026.0	01/22/99
3	Multi-layered osmotic device (Canada)	Pending Allowed	—	CA 2,261,787	01/28/99
4	Multi-layered osmotic device (China)	Pending Allowed	—	CN 98800728.2	01/29/99
5	Multi-layered osmotic device (Japan)	Pending Allowed	—	JP 500972/1999	01/29/99
6	Multi-layered osmotic device (Israel)	Pending Allowed	—	IL 128,043	01/14/99
7	Multi-layered osmotic device (Hong Kong)	HK 1019859	01/30/04	HK 99105177.6	11/10/99
8	Multi-layered osmotic device (U.S. reissue)	Pending	—	US 10/004,772	12/03/01
9	Multi-layered osmotic device (France)	EP 0914098	10/01/03	EP 98925026.0	01/22/99
10	Multi-layered osmotic device (Germany)	EP 0914098	10/01/03	DE 69818607.9	11/27/03
11	Multi-layered osmotic device (Italy)	EP 0914098	10/01/03	EP 98925026.0	03/29/98
12	Multi-layered osmotic device (Spain)	EP 0914098	10/01/03	EP 98925026.0	01/22/99
13	Multi-layered osmotic device (United Kingdom)	EP 0914098	10/01/03	EP 98925026.0	01/22/99
14	Osmotic Device Containing Pseudoephedrine and an H1 Antagonist. (U.S.)	U.S. 6,613,357	09/02/03	U.S. 09/725,655	11/29/00
15	Osmotic Device Containing Pseudoephedrine and an H1 Antagonist. (Europe)	Pending	—	EP 01900942.2	07/09/02
16	Osmotic Device Containing Pseudoephedrine and an H1 Antagonist. (Canada)	Pending	—	CA 2,396,145	01/08/01
17	Osmotic Device Containing Pseudoephedrine and an H1 Antagonist. (U.S.)	Pending	—	U.S. 10/643,011	08/18/03

PATENT